Home > Boards > US OTC > Biotechs >

WPD Pharmaceuticals Inc (CNSX:WBIO)

Add CNSX:WBIO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 9/16/2020 10:13:22 AM - Followers: 5 - Board type: Free - Posts Today: 0






WPD Pharmaceuticals is a diverse biotech company that has 8 novel drug candidates with 4 that are currently in clinical trials today with ongoing
collaborations at MD Anderson Cancer Center, Mayo Clinic, Emory University, Wake Forest University and leading hospitals and academic centers in Poland.
Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust
drug development pipeline with a focus on melanoma, brain cancer, leukemia  and pancreatic cancer. Notably, these funds do not include $14 million USD in
grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.

With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically
positioned to enter the market with blockbuster potential.








WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate

Reduces Coronavirus Replication in Vitro by 100%

To develop in collaboration with CNS Pharmaceuticals antiviral drug candidates licensed

from Moleculin Biotech for the international markets

Email Print Friendly Share
April 09, 2020 03:05 ET Source: WPD Pharmaceuticals

VANCOUVER, British Columbia, April 09, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical companyis pleased to announce that independent research on its WP1122 drug compound found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing. WPD in collaboration with its development partner CNS Pharmaceuticals, Inc. (“CNS”)(Nasdaq: CNSP) intends to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2.

WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech, Inc. (“Moleculin”)(Nasdaq: MBRX). Recently, researchers at the University of Frankfurt disclosed the findings in their article submitted to NatureResearch on March 11, 2020 (Bojkova, D et al; DOI: 10.21203/rs.3.rs-17218/v1) (https://www.researchsquare.com/article/rs-17218/v1). The authors reported that inhibiting glycolysis with non-toxic concentrations of 2-DG completely prevented SARS-CoV–2 replication in Caco–2 cells.  Glycolysis is a process by which cells convert glucose into energy and infected (host) cells are induced by viruses to dramatically increase their dependence on glycolysis.  2-DG inhibits glycolysis because, although it appears to cells to be glucose, it is in fact a decoy that cannot be converted into energy.

WP1122 is referred to as a “prodrug” of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo.  Once administered, these added elements are removed by normal metabolic processes and what remains is 2-DG. As a result, 2-DG is the active compound in WP1122.  In chemical terms, it is referred to as the active “moiety” (subpart) of WP1122.

We are excited with this breakthrough on our WP1122 drug candidate and the early implications are that it could have positive effects on reducing the spread of COVID-19,” commented Mariusz Olejniczak, CEO of WPD. “I would like to commend our license partner, Moleculin and the researchers at the University of Frankfurt for their expedited work and the willingness of the authors to pre-release this data will help support our development of WP1122 for treating COVID-19.”

Walter Klemp, Chairman and CEO of Moleculin added: “This discovery essentially put our development efforts in to turbo-drive.  We are moving as quickly as we can to prepare WP1122 for clinical trials.  With the US and EU having established accelerated approval procedures for COVID-19 related projects, we expect this to move very quickly.  We look forward to WPD’s help, especially as it relates to expediting things in Europe.”

According to WPD’s license partner Moleculin, 2-DG is often referred to as the ‘active moiety’ in WP1122.  The issue with 2-DG is that its often metabolized too quickly by the body, so human tissues and organs can’t get enough concentration to be therapeutic.  Therefore, even though 2-DG is active against a range of viruses, including SARS-CoV-2, it isn’t useful as a clinical therapy because it metabolizes too rapidly.  WP1122 works to solve this problem because it is a ‘prodrug’ of 2-DG.  Its structure enables it to achieve much higher tissue/organ concentrations than 2-DG alone, but once it’s in the cell, it metabolizes into the exact same 2-DG that is so effective in vitro.

About WPD Pharmaceuticals

WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules.  WPD has 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.  The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes 31 countries in Europe and Asia, including Russia.

On Behalf of the Board

‘Mariusz Olejniczak’

Mariusz Olejniczak
CEO, WDP Pharmaceuticals


Investor Relations
Email: investors@wpdpharmaceuticals.com
Tel: 604-428-7050
Web: www.wpdpharmaceuticals.com

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
WBIO News: WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada 10/26/2020 07:30:10 AM
WBIO News: WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials 10/15/2020 07:30:10 AM
WBIO News: WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and... 10/05/2020 07:30:10 AM
WBIO News: WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101 09/16/2020 07:30:10 AM
WBIO News: WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials 09/09/2020 07:30:10 AM
#86   ? CSE: WBIO   WPD Pharmaceuticals Receives Second Prepayment of jejusk 09/16/20 10:13:21 AM
#85   When wpdpf gains the slightest traction it's going jejusk 08/11/20 10:48:55 AM
#84   Yep... Good stuff.. I think wpd is afraid jejusk 07/21/20 10:04:34 AM
#83   $WPDPF: Used to be $WCOTF.......... makinezmoney 07/21/20 08:21:49 AM
#82   Finally! Movement in the right direction jejusk 07/15/20 05:14:29 PM
#81   Is wpdpf ever going to gain some traction!?! jejusk 07/10/20 08:04:46 PM
#80   Thanks, mate. Perhaps we'll see some volume now! jejusk 07/05/20 10:28:07 PM
#79   Yes, your WCOTF shares will become WPDPF shares Renee 07/05/20 09:40:07 PM
#78   New event for me.. what happens to my jejusk 07/05/20 08:08:27 PM
#77   On the U.S. OTC WCOTF for WPD Pharmaceuticals Renee 07/02/20 07:12:38 PM
#76   News.. June 22.. for what it's worth.. https://www.wpdpharmaceuticals.com/news- jejusk 06/25/20 03:14:19 PM
#75   Are these guys going to bring this back jejusk 06/11/20 04:57:51 PM
#74   This on when Wcotf will get out of jejusk 05/29/20 11:29:36 AM
#73   Nice bump today.. Perhaps wpd will gain some jejusk 05/28/20 01:08:55 PM
#72   NEWS!! WPD Pharmaceuticals Licensor Granted Another Key Patent for jejusk 05/28/20 07:33:00 AM
#71   good luck. lucky,mydog 05/19/20 03:06:44 PM
#70   I'm thinking I'll be the proud owner of jejusk 05/19/20 03:06:10 PM
#69   there you go. a trade. lucky,mydog 05/19/20 09:42:18 AM
#68   it's now on the grey market. it's matched lucky,mydog 05/19/20 09:17:50 AM
#67   That's my question... considering this companys connections to jejusk 05/19/20 09:04:42 AM
#66   this didn't trade much before the suspension. lucky,mydog 05/19/20 08:51:22 AM
#65   I'm not sure how that impacts volume...we trade jejusk 05/19/20 08:36:16 AM
#64   it's a foreign company. lucky,mydog 05/19/20 08:33:00 AM
#63   I'm very surprised that this company isn't heavily jejusk 05/19/20 08:25:46 AM
#62   finra resumes trading. lucky,mydog 05/18/20 09:08:56 AM
#61   So this won't begin trading until July? Is jejusk 05/17/20 09:06:17 AM
#60   WPD Pharmaceuticals Inc.: "On May 12, 2020, WPD Renee 05/15/20 05:05:26 PM
#59   All three are connect in various ways, including jejusk 05/06/20 12:45:11 PM
#58   https://www.marketwatch.com/story/sec-takes-action-against-three-more-companies- lucky,mydog 05/05/20 04:31:49 PM
#57   $WCOTF: They'll bring it back again ........... makinezmoney 05/05/20 06:37:39 AM
#56   Only the U.S. OTC stock was suspended and Renee 05/04/20 04:01:31 PM
#55   and now, all three suspended. lucky,mydog 05/04/20 03:14:29 PM
#54   https://www.sec.gov/oiea/investor-alerts-and-bulletins/ia_coronavirus lucky,mydog 05/04/20 03:09:48 PM
#53   https://www.investor.gov/introduction-investing/general-resources/news-alerts/al jejusk 05/04/20 11:54:08 AM
#52   That explains a few things...Does anyone know if jejusk 05/04/20 11:37:32 AM
#51   WPD Pharmaceuticals Inc. WCOTF on the OTC SEC Renee 05/04/20 09:41:04 AM
#50   Can anyone post a Level II photo for jejusk 04/24/20 09:05:46 PM
#49   News out this morning....:) Stocknut 04/21/20 07:49:55 AM
#48   WCOTF Slap the ask .75’s Phoenix300 04/16/20 03:48:29 PM
#47   This looks promising... TwitchChatLiveTV 04/16/20 10:55:40 AM
#46   $10 tomorrow would be nice. marknet 04/14/20 10:00:50 PM
#45   L2 thin... back to dollars today:) Stocknut 04/14/20 09:32:42 AM
#44   Without a doubt:) loading the cheapies:) Stocknut 04/13/20 03:29:05 PM
#43   $WBIO/$WCOTF: Very solid Press Release makinezmoney 04/13/20 03:20:45 PM
#42   https://www.wpdpharmaceuticals.com/_resources/news/Apr-9-2020.pdf Stocknut 04/13/20 03:17:05 PM
#41   Easy double at this level:) Stocknut 04/13/20 01:25:14 PM
#40   $WBIO/$WCOTF: TH2 Patent makinezmoney 04/13/20 01:15:11 PM
#39   $WBIO/$WCOTF: Total Funding............ $89Million makinezmoney 04/13/20 01:08:01 PM
#38   $WBIO/$WCOTF: Another tweet this morning.......... makinezmoney 04/13/20 12:46:42 PM
#37   $WBIO/$WCOTF: MBRX & CNSP both using WP1122 makinezmoney 04/13/20 11:56:07 AM
Consent Preferences